Bioanalysis Zone

Development and validation of an ELISA to study panitumumab pharmacokinetics


Aim: Panitumumab is a monoclonal antibody directed against EGFR that is approved for the treatment of metastatic colorectal cancer. To investigate its pharmacokinetics and concentration–response relationship, a validated assay is required.

Results: An ELISA assay was developed and validated according to international recommendations. Six calibrators (ranging from 0.1 to 20 mg/l) plus one anchor point (50 mg/l) and three

To view restricted content, please:

Click here to read the full article in Bioanalysis.


Leave A Comment